MOLECULAR TEMPLATES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.61 USD | -1.83% |
|
-3.01% | -56.84% |
Presenter SpeechCarter Gould (Analysts)Great. Good morning. My name is Carter Gould, Biotech A...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Companyâs proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.61
USD
Average target price
18
USD
Spread / Average Target
+1,018.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.84% | 10.6M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +7.98% | 23.47B | |
| -13.89% | 21.9B | |
| -6.13% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- MTEM Stock
- News Molecular Templates, Inc.
- Transcript : Molecular Templates, Inc. Presents at 2018 UBS Global Healthcare Conference, May-21-2018 08